

11-2906

Express Mail Label No.: EV 869861412 US
Date of Deposit: November 27, 2006

IFW

Attorney Docket No.: 24492-01071 NATL



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS: Brand et al.
SERIAL NUMBER: 10/555,049 EXAMINER : Not Yet Assigned
INTERNATIONAL April 30, 2004 ART UNIT : Not Yet Assigned
FILING DATE:
FOR: COMBINED USE OF KERATINOCYTE GROWTH FACTOR
AGONISTS AND GASTRIN COMPOUNDS

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TRANSMITTAL LETTER


Transmitted herewith for filing in the present application are the following documents:

1. Information Disclosure Statement (1 page), in duplicate;
2. Modified Form 1449/PTO (2 pages), in duplicate;
3. Copies of Cited References: B1-2; C1-22; and
4. Return Postcard.

If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully requested to contact the undersigned at (617) 542-6000, Boston, Massachusetts.

The Commissioner is authorized to charge any fees that may be due, or to credit any overpayment, to the undersigned's account, Deposit Account No. 50-0311 Ref. No. 24492-007 NATL. A duplicate copy of this transmittal letter is enclosed herewith.

Respectfully submitted,



Ivor R. Elfi, Reg. No. 39,529
David E. Johnson, Reg. No. 41,874
Attorney(s) for Applicants
MINTZ, LEVIN, COHN, FERRIS,
GLOVSKY and POPEO, P.C.


Address all written correspondence to

Customer no.: 30623

Tel: (617) 542-6000

Fax: (617) 542-2241

Date: November 27, 2006



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS: Brand et al.
SERIAL NUMBER: 10/555,049 EXAMINER : Not Yet Assigned
INTERNATIONAL April 30, 2004 ART UNIT : Not Yet Assigned
FILING DATE:
FOR: COMBINED USE OF KERATINOCYTE GROWTH FACTOR
AGONISTS AND GASTRIN COMPOUNDS


Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Applicants make of record the documents listed on the attached modified Form PTO-1449 (submitted in duplicate) in the above-identified application, copies of which are enclosed.

This Information Disclosure Statement is being filed before the mailing date of a first Office Action based on the merits in the above-identified case. Accordingly, no fee or certification is believed due. By the waiver of 37 CFR 1.98(a)(2)(i) copies of the U.S. Patents A1-A3 are not submitted. However, please charge any fees that may be due, or credit any overpayment of same, to Deposit Account No. 50-0311 Reference No. 24492-007 NATL.

Respectfully submitted,


Ivor R. Eljifi, Reg. No. 39,529
David E. Johnson, Reg. No. 41,874
Attorneys for Applicants
MINTZ, LEVIN, COHN, FERRIS,
GLOVSKY and POPEO, P.C.
Address all written correspondence to
Customer no.: 30623
Tel: (617) 542-6000
Fax: (617) 542-2241

Date: November 27, 2006

Please type a plus sign (+) in this box



Modified Form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Application Number	10/555,049
International Filing Date	April 30, 2004
First Named Inventor	Brand
Group Art Unit	Not Yet Assigned
Examiner Name	Not Yet Assigned
Attorney Docket Number	24492-007 NATL

U.S. PATENT DOCUMENTS

Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
	*A1	5,858,977	01/12/99	Aukerman, et al.	514	12	
	*A2	5,885,956	03/23/99	Nardi, et al.	514	2	
	*A3	6,288,301 B1	09/11/01	Nardi, et al.	800	18	

FOREIGN PATENT DOCUMENTS

Exam Initials	Cite No.	Foreign Patent Document Office Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No
	B1	WO 90/08771	RUBIN ET AL.	08/09/90	
	B2	Wo 00/44400	RTP PHARMA INC.; THE GENERAL HOSPITAL CORPORATION	08/03/00	

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	C1	Bonner-Weir, et al. (2000) <i>Proc. Natl. Acad. Sci. U.S.A.</i> , 97:7999-8004.
	C2	Holstad, et al. (1999) <i>J. Endocrinol.</i> , 163:229-234.
	C3	Krakovski, et al. (1999) <i>Am. J. Pathol.</i> , 154:683-691.
	C4	Logothetopoulos, J. (1972) in Handbook of Physiology (Am. Physiol. Soc., Washington, D.C.), <i>Endocrinology</i> , Section 7, Chapter 3, pgs. 67-76.
	C5	Logsdon, et al. (1997) <i>Gastroenterology</i> , 112:A458.
	C6	Lu, et al. (1999) <i>Diabetes</i> , 48:A236.
	C7	Nielsen, et al. (1999) <i>J. Mol. Med.</i> , 77:62-66.
	C8	Okamoto, H. (1999) <i>J. Hepatobiliary Pancreat Surg.</i> , 6:254-262.
	C9	Pierce, et al. (1994) <i>J. Exp. Med.</i> , 179:831-840.
	C10	Playford, et al. (1998) <i>J. Pathol.</i> , 184:316-322.
	C11	Powers, et al. (2000) <i>Endocrine-Related Cancer</i> , 7:165-197.
	C12	Rafaeloff, et al. (1997) <i>J. Clin. Invest.</i> , 99:2100-2109.
	C13	Sharma, et al. (1999) <i>Diabetes</i> , 48:507-513.
	C14	Staiano-Coico, et al. (1993) <i>J. Exp. Med.</i> , 178:865-878.
	C15	Stauffacher, et al. (1970) <i>Proc. Soc. Exp. Biol. Med.</i> , 133:194-200.
	C16	Veves, et al. (2001) <i>J. Clin. Invest.</i> , 107:1215-1218.
	C17	Wang, et al. (1993) <i>J. Clin. Invest.</i> , 92:1349-1356.
	C18	Wang, et al. (1995) <i>Am. J. Physiol.</i> , 268:G1025-G1036.
	C19	Xu, et al. (1999) <i>Diabetes</i> , 48:2270-2276.

Express Mail No.: EV 869861412 US
Date of Deposit: November 27, 2006

Page 2 of 2
Attorney Docket No.: 24492-007 NATL

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS		
Examiner Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	C20	Yamamoto, et al. (2000) <i>Diabetes</i> , 49:2021-2027.
	C21	Yamaoka, et al. (1999) <i>Int. J. Mol. Med.</i> , 3:247-261.
	C22	Yamasaki, et al. (1996) <i>J. Biol. Chem.</i> , 271:15918-15921

* By the waiver of 37 CFR 1.98(a)(2)(i) copies of the U.S. Patents A1-A3 are not submitted.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.